Paxalisib

Kazia Therapeutics presented EVT801 data at the 15th Biennial Ovarian Cancer Research Symposium, showing promising activity in high grade serous ovarian cancer, with 46% of patients having stable disease or partial response.

Aethlon Medical's Hemopurifier® aims to enhance anti-PD-1 therapy by removing tumor-produced extracellular vesicles, with ethics approval for a clinical trial in India following approvals in Australia. The trial will evaluate Hemopurifier® in solid tumor patients with stable or progressive disease during anti-PD-1 monotherapy, with other companies like Immuneering and Iovance Biotherapeutics also advancing immunotherapy treatments.

Aethlon Medical's Hemopurifier®, an immunotherapeutic device for cancer, gains ethics approval in India for a trial in solid tumor patients resistant to anti-PD-1 therapy. The trial aims to assess safety and feasibility, with potential to improve response rates to anti-PD-1 antibodies by removing tumor-produced extracellular vesicles.

July's Molecules of the Month feature Novartis' molecular glue degrader for sickle cell disease, Pfizer's tinlorafenib for melanoma with brain metastasis, AstraZeneca's AZ-PRMT5i-1 for MTAP-deficient cancers, MTX-531 for dual EGFR/PI3K inhibition, and LifeMine Therapeutics' XC219 discovered via top-down approach. Paxalisib shows promising data in glioblastoma, and Takeda's OX2R-selective agonist offers potential in Alzheimer's disease.

2024-2025 saw significant advancements in cancer treatment, including FDA approvals for new therapies, promising clinical trial results, and discussions on treatment strategies for various cancers. Key developments include enasidenib for IDH2-mutated AML, ropeginterferon alfa-2b for essential thrombocythemia, and new drug applications for recurrent glioma and ovarian cancer treatments.